New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence

Transplant International

Volumn 27, Issue 10, 2014, Pages 1022-1028

  Cholongitas, Evangelos ^a   Goulis, Ioannis ^a   Antoniadis, Nikolaos ^b   Fouzas, Ioannis ^b   Imvrios, George ^b   Papanikolaou, Vasilios ^b   Akriviadis, Evangelos ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

entecavir; glomerular filtration rate; hepatitis B recurrence; liver transplantation; renal function; tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; TENOFOVIR; ADENINE; GUANINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT VIRUS INFECTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; HISTOCOMPATIBILITY; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; RETREATMENT; RISK ASSESSMENT; TREATMENT OUTCOME; VIROLOGY;

ADENINE; ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; GUANINE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; RECURRENCE; RETREATMENT; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 84925670307     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12370     Document Type: Article

References (21)

1. Cholongitas E, Papatheodoridis GV,. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19: 9189.
2. Peng CY, Chien RN, Liaw YF,. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442.
3. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK,. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294.
4. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al,. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109.
5. Vlachogiannakos J, Papatheodoridis G,. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19: 8822.
6. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176.
7. Cholongitas E, Papatheodoridis GV,. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353.
8. Saab S, Desai S, Tsaoi D, et al,. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511.
9. Teperman LW, Poordad F, Bzowej N, et al,. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013; 19: 594.
10. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E,. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479.
11. Wesdorp DJ, Knoester M, Braat AE, et al,. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013; 58: 67.
12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
13. Levey AS, Stevens LA, Schmid CH, et al,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
14. Bagga A, Bajpai A, Menon S,. Approach to renal tubular disorders. Indian J Pediatr 2005; 72: 771.
15. Buti M, Mas A, Prieto M, et al,. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811.
16. Naoumov NV, Lopes AR, Burra P, et al,. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888.
17. Stravitz RT, Shiffman ML, Kimmel M, et al,. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32: 1138.
18. Tanaka T, Renner EL, Selzner N, Therapondos G, Lilly LB,. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol 2014; 28: 41.
19. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW,. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268.
20. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167.
21. Pipili CL, Papatheodoridis GV, Cholongitas EC,. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 2013; 84: 880.